Ozempic and Wegovy share the same active ingredient, semaglutide, but in Australia they're approved for two different purposes.
Same medicine, different purpose
Ozempic is approved and PBS-subsidised for managing blood sugar in adults with type 2 diabetes, and for reducing cardiovascular risk in that group. Wegovy is approved for weight management in adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition like high blood pressure. There's currently no PBS subsidy for Wegovy.
How they work
Both medicines are GLP-1 receptor agonists. They mimic a hormone your gut releases after eating, which helps regulate insulin production and signals to your brain that you're full. This is why they're used for both blood sugar management and appetite regulation, depending on the dose and intended use.
Dosing differs
Ozempic pens are available in 0.25 mg, 0.5 mg, 1 mg or 2 mg doses, typically titrated upward as needed. Wegovy pens go up to 2.4 mg, usually starting at 0.25 mg weekly and increasing gradually over several months to a maintenance dose.
What the evidence shows
Clinical trials have shown meaningful weight loss with Wegovy, though benefits can fade if the medication is stopped, research suggests a large share of lost weight is regained within a year of discontinuing. The most common side effects for both medicines are nausea and vomiting, though more serious risks like gallbladder issues have also been reported.
Whether Ozempic or Wegovy might be appropriate for you depends on your individual health circumstances, and needs to be assessed by your GP or prescriber, not chosen off the back of a blog post.
